The next MS breakthrough treatment may be in the works with a stem cell product called MultiStem. The proprietary and patented product is manufactured by Athersys, Inc. It is a biological product made from human stem cells that originate from adult bone marrow. Since it doesn’t require embryonic stem cells, the first source of concern is eliminated in that there won’t be attempts to block its development by activist groups opposed to the use of the embryo cells.

The potential MS breakthrough treatment is different from other stem cell technologies in that after they are isolated from the donor, the MultiStem product can be reproduced on a large scale for further use and can even be stored in a frozen state for future use.  When the cells are obtained from a single donor, they don’t require any genetic modification so they can be put to use in banks that can …